Royal Philips announced that it has received 510(k) clearance from the US Food and Drug Administration (FDA) to market its Spectral Diagnostic Suite (SpDS), a set of advanced visualization and analysis tools designed for the Philips IQon Spectral CT to deliver enhanced spectral viewing and clinical applications.
According to Philips, the SpDS is flexible and provides spectral capabilities within traditional CT applications, which allows users to access clinical and spectral information “on-demand” to achieve better clinical decision support without any added complexity of special modes or workstations that disrupt user workflow. Philips SpDS was designed to eliminate the need to bring the patient back for additional imaging, and the suite’s on-demand spectral analysis of a particular region allows the physician to further analyze incidental findings while also reducing dose exposure to the patient.
The Philips SpDS is also designed to allow for viewing and analysis of spectral datasets in a variety of settings: a reading room, on picture archiving and communication systems (PACS), or from remote locations.
The Philips SpDS package includes spectral enhanced comprehensive cardiac analysis (sCCA), spectral enhanced advanced vessel analysis (sAVA), and spectral enhanced tumor tracking (sTT).
For more information on Philips IQon Spectral CT and the Philips Spectral Diagnostic Suite, visit the Philips website.